Safety and Efficacy of Albiglutide in Type 2 Diabetes

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Glucagon-Like Peptide 1; Metformin; Pioglitazone; rGLP-1 protein

Criteria

Inclusion Criteria:

• type 2 diabetes

• BMI 20-45kg/m2

Exclusion Criteria:

• NYHA Class II to IV heart failure

• females who are pregnant, lactating, or less than 6 weeks post-partum